Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

Mariam A. Stoff-Khalili, Angel A. Rivera, J. Michael Mathis, N. Sanjib Banerjee, Amanda S. Moon, A. Hess, Rodney P. Rocconi, T. Michael Numnum, M. Everts, Louise T. Chow, Joanne T. Douglas, Gene P. Siegal, Zeng B. Zhu, Hans Georg Bender, Peter Dall, Alexander Stoff, Larissa Pereboeva, David T. Curiel

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Purpose: Alternative and complementary therapeutic strategies need to be developed for metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of cancer in which the replicating virus itself is the anticancer agent. However, the success of virotherapy has been limited due to inefficient virus delivery to the tumor site. The present study addresses the utility of human mesenchymal stem cells (hMSCs) as intermediate carriers for conditionally replicating adenoviruses (CRAds) to target metastatic breast cancer in vivo. Experimental design: HMSC were transduced with CRAds. We used a SCID mouse xenograft model to examine the effects of systemically injected CRAd loaded hMSC or CRAd alone on the growth of MDA-MB-231 derived pulmonary metastases (experimental metastases model) in vivo and on overall survival. Results: Intravenous injection of CRAd loaded hMSCs into mice with established MDA-MB-231 pulmonary metastatic disease homed to the tumor site and led to extended mouse survival compared to mice treated with CRAd alone. Conclusion: Injected hMSCs transduced with CRAds suppressed the growth of pulmonary metastases, presumably through viral amplification in the hMSCs. Thus, hMSCs may be an effective platform for the targeted delivery of CRAds to distant cancer sites such as metastatic breast cancer.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalBreast Cancer Research and Treatment
Volume105
Issue number2
DOIs
StatePublished - 1 Oct 2007

Fingerprint

Mesenchymal Stromal Cells
Adenoviridae
Breast Neoplasms
Neoplasm Metastasis
Lung
Human Adenoviruses
Neoplasms
Viruses
SCID Mice
Growth
Heterografts
Intravenous Injections
Antineoplastic Agents
Lung Diseases
Research Design
Theoretical Models
Therapeutics
Survival

Keywords

  • Breast cancer
  • CRAds
  • Cell vehicle
  • Metastases
  • Stem cells
  • Virotherapy

Cite this

Stoff-Khalili, Mariam A. ; Rivera, Angel A. ; Mathis, J. Michael ; Banerjee, N. Sanjib ; Moon, Amanda S. ; Hess, A. ; Rocconi, Rodney P. ; Numnum, T. Michael ; Everts, M. ; Chow, Louise T. ; Douglas, Joanne T. ; Siegal, Gene P. ; Zhu, Zeng B. ; Bender, Hans Georg ; Dall, Peter ; Stoff, Alexander ; Pereboeva, Larissa ; Curiel, David T. / Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. In: Breast Cancer Research and Treatment. 2007 ; Vol. 105, No. 2. pp. 157-167.
@article{2a168b95246e48dfb239109737140193,
title = "Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma",
abstract = "Purpose: Alternative and complementary therapeutic strategies need to be developed for metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of cancer in which the replicating virus itself is the anticancer agent. However, the success of virotherapy has been limited due to inefficient virus delivery to the tumor site. The present study addresses the utility of human mesenchymal stem cells (hMSCs) as intermediate carriers for conditionally replicating adenoviruses (CRAds) to target metastatic breast cancer in vivo. Experimental design: HMSC were transduced with CRAds. We used a SCID mouse xenograft model to examine the effects of systemically injected CRAd loaded hMSC or CRAd alone on the growth of MDA-MB-231 derived pulmonary metastases (experimental metastases model) in vivo and on overall survival. Results: Intravenous injection of CRAd loaded hMSCs into mice with established MDA-MB-231 pulmonary metastatic disease homed to the tumor site and led to extended mouse survival compared to mice treated with CRAd alone. Conclusion: Injected hMSCs transduced with CRAds suppressed the growth of pulmonary metastases, presumably through viral amplification in the hMSCs. Thus, hMSCs may be an effective platform for the targeted delivery of CRAds to distant cancer sites such as metastatic breast cancer.",
keywords = "Breast cancer, CRAds, Cell vehicle, Metastases, Stem cells, Virotherapy",
author = "Stoff-Khalili, {Mariam A.} and Rivera, {Angel A.} and Mathis, {J. Michael} and Banerjee, {N. Sanjib} and Moon, {Amanda S.} and A. Hess and Rocconi, {Rodney P.} and Numnum, {T. Michael} and M. Everts and Chow, {Louise T.} and Douglas, {Joanne T.} and Siegal, {Gene P.} and Zhu, {Zeng B.} and Bender, {Hans Georg} and Peter Dall and Alexander Stoff and Larissa Pereboeva and Curiel, {David T.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1007/s10549-006-9449-8",
language = "English",
volume = "105",
pages = "157--167",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

Stoff-Khalili, MA, Rivera, AA, Mathis, JM, Banerjee, NS, Moon, AS, Hess, A, Rocconi, RP, Numnum, TM, Everts, M, Chow, LT, Douglas, JT, Siegal, GP, Zhu, ZB, Bender, HG, Dall, P, Stoff, A, Pereboeva, L & Curiel, DT 2007, 'Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma', Breast Cancer Research and Treatment, vol. 105, no. 2, pp. 157-167. https://doi.org/10.1007/s10549-006-9449-8

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. / Stoff-Khalili, Mariam A.; Rivera, Angel A.; Mathis, J. Michael; Banerjee, N. Sanjib; Moon, Amanda S.; Hess, A.; Rocconi, Rodney P.; Numnum, T. Michael; Everts, M.; Chow, Louise T.; Douglas, Joanne T.; Siegal, Gene P.; Zhu, Zeng B.; Bender, Hans Georg; Dall, Peter; Stoff, Alexander; Pereboeva, Larissa; Curiel, David T.

In: Breast Cancer Research and Treatment, Vol. 105, No. 2, 01.10.2007, p. 157-167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

AU - Stoff-Khalili, Mariam A.

AU - Rivera, Angel A.

AU - Mathis, J. Michael

AU - Banerjee, N. Sanjib

AU - Moon, Amanda S.

AU - Hess, A.

AU - Rocconi, Rodney P.

AU - Numnum, T. Michael

AU - Everts, M.

AU - Chow, Louise T.

AU - Douglas, Joanne T.

AU - Siegal, Gene P.

AU - Zhu, Zeng B.

AU - Bender, Hans Georg

AU - Dall, Peter

AU - Stoff, Alexander

AU - Pereboeva, Larissa

AU - Curiel, David T.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: Alternative and complementary therapeutic strategies need to be developed for metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of cancer in which the replicating virus itself is the anticancer agent. However, the success of virotherapy has been limited due to inefficient virus delivery to the tumor site. The present study addresses the utility of human mesenchymal stem cells (hMSCs) as intermediate carriers for conditionally replicating adenoviruses (CRAds) to target metastatic breast cancer in vivo. Experimental design: HMSC were transduced with CRAds. We used a SCID mouse xenograft model to examine the effects of systemically injected CRAd loaded hMSC or CRAd alone on the growth of MDA-MB-231 derived pulmonary metastases (experimental metastases model) in vivo and on overall survival. Results: Intravenous injection of CRAd loaded hMSCs into mice with established MDA-MB-231 pulmonary metastatic disease homed to the tumor site and led to extended mouse survival compared to mice treated with CRAd alone. Conclusion: Injected hMSCs transduced with CRAds suppressed the growth of pulmonary metastases, presumably through viral amplification in the hMSCs. Thus, hMSCs may be an effective platform for the targeted delivery of CRAds to distant cancer sites such as metastatic breast cancer.

AB - Purpose: Alternative and complementary therapeutic strategies need to be developed for metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of cancer in which the replicating virus itself is the anticancer agent. However, the success of virotherapy has been limited due to inefficient virus delivery to the tumor site. The present study addresses the utility of human mesenchymal stem cells (hMSCs) as intermediate carriers for conditionally replicating adenoviruses (CRAds) to target metastatic breast cancer in vivo. Experimental design: HMSC were transduced with CRAds. We used a SCID mouse xenograft model to examine the effects of systemically injected CRAd loaded hMSC or CRAd alone on the growth of MDA-MB-231 derived pulmonary metastases (experimental metastases model) in vivo and on overall survival. Results: Intravenous injection of CRAd loaded hMSCs into mice with established MDA-MB-231 pulmonary metastatic disease homed to the tumor site and led to extended mouse survival compared to mice treated with CRAd alone. Conclusion: Injected hMSCs transduced with CRAds suppressed the growth of pulmonary metastases, presumably through viral amplification in the hMSCs. Thus, hMSCs may be an effective platform for the targeted delivery of CRAds to distant cancer sites such as metastatic breast cancer.

KW - Breast cancer

KW - CRAds

KW - Cell vehicle

KW - Metastases

KW - Stem cells

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=34447510789&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9449-8

DO - 10.1007/s10549-006-9449-8

M3 - Article

C2 - 17221158

AN - SCOPUS:34447510789

VL - 105

SP - 157

EP - 167

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -